News Agency
Men's Weekly

Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023

  • Written by PR Newswire

HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid leukemia (AML) at the 65th American Society of...

Read more: Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly...

Aligning Social, Email, and Web Campaigns with Structured Content: Building a Unified Marketing Engine

Few modern marketing campaigns exist in a bubble. A product launch, for example, may kick off with social media buzz, continue into a targeted email campaign, and finish with a conversion-focused web experience. Ideally, all three touchpoints communicate the same... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion